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Abstract: 
Antibiotics have revolutionised the treatment of bacterial infections. However, it is 
widely held that there is underinvestment in antibiotics research and development 
relative to the socially optimal level for a number of reasons. In this paper we 
discuss whether existing Health Technology Assessment (HTA) procedures 
recognise the full economic and societal value of new antibiotics to patients and 
society when making reimbursement decisions.  We present three 
recommendations for modelling the unique attributes of value that are specific to 
novel antibiotics. We find, based on a review of the literature, that some of the 
value elements proposed by our framework have previously been discussed 
qualitatively by HTA bodies when evaluating antibiotics, but are not yet formally 
captured via modelling.  We present a worked example to show how it may be 
possible to capture these dimensions of value in a more quantitative manner.  We 
conclude by answering the question of the title as follows: the unique attributes of 
novel antibiotics should be considered in reimbursement decision making, in a way 
which captures the full range of benefits these important technologies bring to 
patients, healthcare systems, and society.  
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Introduction 
Antibiotics have changed the way we treat bacterial infections and transformed medicine. Like 
other biomedical technologies, antibiotics are subject to health technology assessment (HTA) 
procedures to evaluate the clinical, cost-effectiveness, safety, legal and ethical implications1-3. 
HTA is widely used to support pricing and reimbursement decisions and the development of 
guidelines about appropriate use4-7. The unique challenges associated with demonstrating the 
value of novel antibiotics has been well articulated by Karlsberg Schaffer et al8.  In this paper, 
we offer one approach to capture some of the unique elements of value quantitatively, 
particularly in systems that employ a cost-effectiveness analysis approach to evaluate new 
technologies for reimbursement. 
It has been argued that the market for antibiotics is subject to market failure, with the result 
that pharmaceutical companies are underinvesting in antibiotic research relative to the socially 
optimal level9-11. This market failure arises from the presence of significant externalities, both 
positive and negative, which arise from the transmission of infection and the possibility of the 
emergence and spread of resistant micro-organisms. There is gathering global momentum to 
put in place incentive mechanisms to facilitate the discovery of new antibiotics.   
A critical question is: what is the price worth paying for a novel antibiotic that can treat drug 
resistant infections?  In particular, we argue that the value of novel antibiotics, in terms of their 
ability to reduce transmission rates in the general population (transmission value), and the 
potential to curb resistance through a reduction in selection pressure (diversity value), are 
important elements to consider in the assessment of the full benefit that antibiotics offer to 
patients, health care systems and society. To do would provide an accurate valuation of these 
technologies based on sound economic theory, and ensure appropriate supply-side incentives. 
Framework for Health Technology Assessment of antibiotics 
According to the World Health Organization12 (WHO), “Health technology assessment (HTA) 
refers to the systematic evaluation of properties, effects, and/or impacts of health technology. 
It is a multidisciplinary process to evaluate the social, economic, organisational and ethical 
issues of a health intervention or health technology.”  Yet, conducting HTA for antibiotics and 
other antimicrobials is challenging because of the externalities associated with antibiotic 
use13,14.  One aim of this paper is to show how to draw on background economic theory to 
arrive at a practical assessment framework.   
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A standard ratio used to evaluate new medical technologies in health systems where cost-
effectiveness is an important consideration for decision making is the Incremental Cost 
Effectiveness Ratio (ICER).  NICE15 defines the ICER as “The ratio of the difference in the 
mean costs of a technology compared with the next best alternative to the differences in the 
mean outcomes” (p 85), that is to say the ratio of incremental costs to incremental benefits.  In 
the case of noncommunicable diseases, this ICER can be interpreted as shown in (1). 
𝐼𝐶𝐸𝑅 =
𝑐
𝑣
 (1) 
In this ratio c is the patient-level incremental cost and v is the incremental benefit to patients 
receiving treatment, normally measured in units such as Quality Adjusted life years (QALYs).  
Such an interpretation is entirely appropriate for technologies to treat noncommunicable 
illness.  However, in the case of infectious disease there are costs and benefits from the 
transmission of disease.  How should these additional considerations be included in the ICER?  
The standard guidelines on how to perform cost-effectiveness analyses are surprisingly quiet 
on this point – even the IDSI Reference Case16, which is intended for use in Low and Middle-
Income Countries has little to say, despite the much greater disease burden associated with 
infectious disease in these countries.  Certainly, guidelines on economic Cost-Benefit Analysis 
tend to err on the side of inclusion: for example the UK Treasury Green Book17 recommends 
that ‘The relevant costs and benefits to government and society of all options should be 
valued… In this context, relevant costs and benefits are those that can be affected by the 
decision at hand [our italics]’.  Yet HTA, where it uses cost-effectiveness analysis, tends to use 
some form of Cost-Utility Analysis which often excludes particular costs and particular 
benefits. 
There has been a significant discussion about the theoretic foundations of the Cost-Utility 
Analysis and the reasons why Cost-Utility Analysis excludes particular considerations which 
would be included (and indeed monetised) in a more comprehensive Cost-Benefit Analysis (for 
a recent review see e.g. Chapter 2 of Neumann et al3).  The narrowest interpretation of Cost-
Utility Analysis is that analysis should focus on concerns which fall within the mandate of the 
Minister of Health: thus productivity impacts or impact on income tax receipts are typically 
excluded in a Cost-Utility Analysis when the decision maker perspective is taken.  However, 
on this criterion, there seems to be no justification for excluding the wider costs and benefits 
of using an antibiotic, beyond the patients treated, as long as these costs fall on the health 
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systems, and the benefits are experienced in the form of health by the patient population of the 
health system.  Therefore we conclude that even on narrowest interpretation of CUA, costs and 
benefits from changes in the transmission pattern should be included in the analysis.  Hence, 
in this paper we propose the modified ICER shown in (2) as being more fully conformant with 
the health economic theoretical base of HTA.  The costs and benefits should be understood as 
being incremental to the current standard of care. 
𝐼𝐶𝐸𝑅𝐴𝐵𝑋 =
𝐶 − 𝑆 − 𝑆𝑡 − 𝑆𝑑
𝑉 + 𝑉𝑡+𝑉𝑑
 
(2) 
In (2), V is the direct benefit of using the new antibiotic for the population of interest, i.e., 
heuristically, if each of the N people benefit to the tune of v QALYS, then V=Nv.  It is important 
to highlight that assessing the direct benefits of antibiotics may be challenging given the nature 
of the evidence base for these technologies, particularly in view of the difficulty of conducting 
superiority studies8,18,19.  
Vt is the benefit of reduced transmission of the disease to the rest of the population, in terms of 
QALYs from avoided infections. Vd is the “diversity value” – the benefit at the population level 
of protecting the existing portfolio of antibiotics, in terms of QALYs flowing from the 
avoidance of other resistant infections.  C is the total purchase and administration cost of using 
the antibiotic for the population of interest: heuristically, if N people are treated, then C=Nc.  S 
is the total cost savings (for example in avoided treatment and reduced bed-days) for the treated 
population, and St and Sd are the cost savings from avoided transmission and protection of 
existing antibiotics.  We assume that appropriate economic discount rates are applied to all 
terms. Assessing the values of these parameters is not straightforward as it will depend on the 
state of resistance to all the drugs which may be used to treat the target condition. 
The framework which we have presented flows from prior discussions in the literature about 
the economic aspects of the antibiotic resistance13,14,20,21.  We now discuss the 
recommendations which our framework implies.   These recommendations are the consensus 
view of the authors, based on review of the literature and exposure to policy dialogue in this 
area, and reflections on the implications of the framework for practice, informed by the 
empirical study of current practice reported in the following section. 
Recommendation 1.  Assessment should, as appropriate, include a sensitivity analysis of the 
impact of resistance to the new antibiotic, both initially and over time.  For example, a simple 
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way to model resistance is by means of an exponential decay rate.  In this case, sensitivity 
analysis could take the form of a one-way parametric sensitivity analysis on the parameter 
capturing the resistance rate.  In future work, there may also be value in exploring more 
complex mathematical formulations that take into account complexities around genetic 
selection, pathogen diversity, fitness costs and transmission. 
Using an antibiotic has both positive and negative externalities20. The negative externality 
arises because every time the antibiotic is used, it creates selecting pressure for resistant 
bacteria.  The current recommendation goes beyond standard the standard recommendation to 
use sensitivity analysis in cost-effectiveness analysis as we are recommending that in the case 
of antibiotics, sensitivity is reported on the resistance parameter specifically. The rationale for 
this recommendation is that the extent of this externality is hard to predict and depends on both 
the mode and volume of use of the antibiotic: in general antibiotics should be used with care to 
forestall the emergence of resistance.  In the case of broad-spectrum antibiotics, the selection 
pressure associated with use of an antibiotic can impact both the targeted pathogen and other 
bacteria and this additional cost may need to be included as an extra term in Equation 2. 
However, we focus on the case of a novel, narrow-spectrum therapy in this paper.  The positive 
externalities we consider under recommendation 3 below.  
Recommendation 2. Analysis should take place at the population level. 
There is a strong argument for HTA agencies to consider population level costs and benefits to 
account for externalities associated with antibiotic use. To implement this change, the parties 
conducting the assessment must have the appropriate level of scope. In some countries (e.g. 
Germany and UK) novel inpatient antibiotics are currently assessed by regional or local payers 
at the hospital level. Yet savings due to transmission and avoided hospitalisation may not be 
captured if the assessment is not done by an assessment body at the appropriate regional or 
national level.  If local or regional payers are reluctant to withhold access to antibiotics on 
grounds of a mismatch between prices and the benefits which they see locally, central 
authorities may wish to meet the costs from central funds (as is the case for vaccination, eg in 
the UK).  
 
Recommendation 3.  In addition to the direct costs and benefits associated with treating one 
patient with an antibiotic, where relevant, the following benefits should also be taken into 
account: 
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3.a. Indirect benefits from avoided onward transmission 
These are the benefits which accrue from the prevention of transmission from the 
infected patient to others.  Developing a true dynamic disease model which captures 
these disease dynamics is a significant undertaking, and for some diseases may not even 
be possible due to inadequate scientific understanding of transmission dynamics.  If a 
reliable and validated dynamic disease is available, it should of course be used.  
However, often analysts face a choice between fully incorporating these benefits at 
considerable time and expense, omitting these indirect benefits from the analysis 
(which means that the overall benefit assessment will be conservative), or incorporating 
them in a heuristic way which may be open to challenge.  Jit and Brisson22 provide a 
useful guide to the modelling trade-offs for such decisions.   
3.b. Diversity benefits from the protective effects on existing antibiotics currently in use 
An important argument for the introduction of a new antibiotic is that it removes the 
selection pressure from existing antibiotics that are currently in use21. However the 
science of modelling through the impact of a change in treatment on the resistance 
profile of competing antibiotics, not to mention the health impacts associated with this 
change in resistance is still in its early stages. We consider that the best available 
approach at this point to assessing the diversity benefit, if such benefits are believed to 
be significant, is to assemble a panel of experts and conduct a formal expert elicitation 
exercise.  Expert elicitation has been increasingly and widely used in HTA in recent 
years, in questions for which relevant scientific knowledge exists but there is not yet 
scientific consensus or compelling empirical evidence23,24. 
The main questions of this paper are whether such recommendations are currently followed, 
and whether they are feasible within the constraints of HTA practice. 
Survey of current practice in the assessment of antibiotics  
We conducted a review of HTA assessments of antibiotics across the EU in order to understand 
how HTA agencies currently assess antibiotics, comparing against the framework outlined in 
the previous section. Only agencies who published their recommendations in English, German, 
Spanish, French and/or Dutch were included. We were able to include in our analysis 5 nations 
and 8 different agencies (HAS from France, IQWiG and DIMDI from Germany, ZI from 
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Netherlands, AETS from Spain, SMC from Scotland, NICE from England and AWMSG from 
Wales). 
To establish which reports to evaluate, we examined the list of publications available at the 
website of each selected agency from 2000 through April 2016, and selected those related to 
antibiotics that contained complete HTA reports (defined as those ones who included at least a 
comparative clinical effectiveness, efficacy, safety and economic assessment of the drug). 
After the online search, each agency was directly contacted to request additional antibiotic 
HTA reports. For comparison purposes, the selected antibiotic was required to have gone 
through the full HTA process in at least two of the selected HTA agencies.  
From each selected antibiotic HTA report, we reviewed and looked for mention of the unique 
characteristics of antimicrobials taken into consideration by each individual agency, 
particularly relating to the development spread of resistance.  In total, these agencies produced 
35 antibiotic HTA reports, of which 17 were determined to fulfil our inclusion criteria (4 from 
HAS, 1 from IQWiG, 2 from ZI, 4 from SMC, 3 from NICE and 3 from AWMSG). 
Based on the aforementioned criteria, the following antibiotics were selected:  
1. Aztreonam lysine (Cayston®) 75 mg powder and solvent for nebuliser solution by Gilead 
Sciences 
2. Ceftaroline fosamil (Zinforo®) 600 mg powder for concentration for solution for infusion 
by AztraZeneca 
3. Colistimethate sodium (Colobreathe®) 1,662,500 IU hard capsules, inhalation powder by 
Forest Laboratories 
4. Fidaxomicin (Dificlir®) 200 mg film-coated tablets by Astellas Pharma 
5. Tigecycline (Tygacil®) 50 mg vial of powder for intravenous infusion by Wyeth 
The results of the review were as follows:  
• When evaluating ceftaroline fosamil, both SMC and AWMSG made brief comments 
concerning the development of resistance. HAS specifically had concerns regarding a 
secondary indication for community-acquired pneumonia (CAP) due to the high risk of 
developing resistance, the broad spectrum nature and the availability of narrower-spectrum 
antibiotics.  
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• HAS was able to evaluate resistance by comparing the percentage of drug-resistant isolates 
of Colistimethate sodium against tobramycin after 0 and 24 weeks of use, but NICE did not 
mention this point.  
• Tigecycline was evaluated by SMC and HAS. The latter briefly discussed the necessity of 
new drugs with new mechanisms of action and that tigecycline will likely provide 
additional treatment options for managing infectious diseases (potentially indicating 
awareness of the importance of diversity in protecting against the spread of resistance).  
• When reviewing fidaxomycin, AWMSG acknowledged the benefit of a new class of 
antibiotic with a novel mechanism of action, and showed concern for the development of 
future resistance against this new product. The Dutch ZI and French HAS only made brief 
comments related to the possibility of developing resistance; in addition, the latter makes 
reference to the introduction of fidaxomicin as an additional tool in helping reducing the 
spread of resistant bacteria. NICE (through a NICE-advice report) and SMC did not address 
any issues relating to transmission or diversity value in their respective reports.  
To further provide a qualitative sense of the way in which the components of our framework 
surface, we focus on the case of fidaxomycin  where we found explicit recognition of 
transmission and diversity value in reports from the AWMSG and HAS: 
CHMP [Committee for Medicinal Products for Human Use] also noted that fidaxomicin 
belongs to a novel antibiotic class, which it considered important from an antibiotic 
resistance perspective, as it limits the risks for cross-resistance25. 
Under satisfactory conditions of use, this proprietary medicinal product may have an 
impact in terms of reducing the ecological risk linked to the spread of resistant bacteria. 
[fidaxomicin] is therefore likely to provide a partial response to a public health need. 26. 
We conclude from this review that there is awareness of the distinctive nature and dimension 
of value of antibiotics within HTA agencies, and these considerations do surface in discussions 
about assessment, and may be taken into account qualitatively.  However, standard HTA 
methods do not include the additional sources of value of antibiotics in a systematic way, 
although the background health economic theory which guides HTA suggests that they 
should.  This challenge is recognised for example by the European Commission27 call for 
“develop new or improved methodological HTA approaches and foster methodological 
consensus-building.”   
Methods 
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Worked example: CRAB monotherapy treatment 
In order to demonstrate how analysis might be conducted in line with the recommendations 
above, we present a worked example. The model is based on a hypothetical antibiotic described 
by Spellberg and Rex28 (henceforth, SR), who conducted a cost-effectiveness analysis 
associated with the introduction of the new antibiotic in the United States.  The purpose of this 
is not to conduct an actual analysis which would support reimbursement decisions about this 
antibiotic (since it does not, in fact, exist) but to sketch how an antibiotic might be assessed 
using the ideas of our framework. 
The hypothetical SR monotherapy targets Carbapenem-Resistant Acinetobacter baumannii 
(CRAB), which is a resilient micro-organism, with the ability to survive in the environment for 
long periods of time by acquiring resistance genes, rendering the infections they cause unable 
to be treated by certain antibiotics. The Carbapenem class of antibiotics are last line drugs that 
are often used to treat multi-drug resistant infections within hospitals, particularly intensive 
care units (ICUs). Therefore, CRAB is considered an important infection-causing organism 
within the ICU setting. For simplicity we assume a 100% therapy uptake rate. 
In order to estimate the benefits associated with this hypothetical monotherapy being adopted 
in Europe, we adapted the methods used in SR and applied them to the European incidence 
statistics of CRAB infections. Data from the ECDC point prevalence survey29 was used to 
estimate the incidence of CRAB infections in Europe, by extracting the incidence of healthcare 
associated infections and applying A. baumannii infection and Carbapenem resistance rates, as 
presented in equation (3) and Table 1. 
 
CRAB incidence = Health Associated Infections (HAI) incidence in Europe × % of 
Acinetobacter baumannii infections × Carbapenem resistance rate   (3) 
 
Table 1 about here 
Our equation (2) contains terms relating to benefits and savings from both direct treatment and 
avoided transmission.  To assess these benefits, we start with the existing annual incidence of 
CRAB infections in Europe. We then consider a scenario where the new monotherapy has been 
in use for some time and therefore annual incidence been reduced by x% due to avoided 
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transmission.  In this new steady state, (1-x) % of the current incidence will contribute to direct 
treatment benefits and x % will contribute to the transmission benefits.   
Insights into the value of x can be obtained from dynamic disease modelling. A dynamic disease 
model for A. baumannii is presented in Doan et al30. Within the model, 98% of A. baumannii 
transmission was estimated as environmental, driven by bacterial shedding from individuals 
both colonised and infected with A. baumannii, as opposed to direct transmission between 
patients within the ICU. CRAB monotherapy targets the bacterial shedding by removing CRAB 
from infected patients and therefore reducing the source of environmental bacteria. The 
bacterial shedding rates estimated by the paper give us a basis for estimating the reduced 
transmission offered by the monotherapy.  According to the bacterial shedding rates within this 
model, infected individuals account for 43% of all bacterial shedding into the environment. 
Assuming a 100% therapy uptake rate targeting infected individuals, we use a 40% reduction 
in transmission of overall CRAB infections, after one year of CRAB monotherapy being 
introduced as the primary treatment option for suspected CRAB infections.   
In order to estimate the costs, savings and benefits for the fraction of the population receiving 
curative treatment, we used the methods of SR directly. The costs for resistant infections were 
extracted from SR (converting dollars into euros) whilst the price of a course of the new 
monotherapy was set at €25,000 (€16,000 more than estimated by SR), in order to provide a 
“worst case scenario” of the new monotherapy.  The life years gained and the quality of those 
life years for each treated patient were extracted from SR. Key parameters are shown in Table 
2, with the lowest and highest estimates for sensitivity analysis purposes where appropriate, as 
well as the resulting computed European incidence rates.  Costs, savings and benefits are 
calculated using the equations (4), (5) and (6): 
Direct cost (C) = CRAB incidence ×  (1-Reduced transmission rate) × cost of novel 
therapy                      (4) 
 
Direct Savings (S) = CRAB incidence × (1-Reduced transmission rate) × cost of 
treating resistant case x cost reduction per effective therapy                (5) 
 
12 
 
Direct benefits (V) = CRAB incidence × (1-Reduced transmission rate) × reduced 
mortality rate × life years gained × utility value of quality of life gained    (6) 
  
Table 2 about here 
 
In order to estimate the savings and benefits accruing from avoided transmission, that is the 
benefit enjoyed by the fraction the population which does not experience illness as a result of 
the use of the new monotherapy by other people, we model as shown in equations (7) and (8). 
The cost of treating a resistance case in equation (7) is the cost of treatment with the old 
technology because, in the counterfactual world in which the new technology does not exist, 
these patients would be treated with the old technology. 
 
Transmission savings (St) = CRAB incidence × reduced transmission rate × cost of 
treating resistant case.           (7) 
 
Transmission benefits (Vt) = CRAB incidence ×  reduced transmission rate x CRAB 
mortality rate ×  life years gained from avoided infection ×  utility value of quality of 
life gained from avoided infection                                                       (8) 
The original CRAB mortality rate was applied since these individuals avoided a CRAB 
infection altogether. In addition, both the life years gained and quality improvement were 
increased, with the reasoning of improved life quality following the prevention of an infection, 
as opposed to recovery following treatment (Table 3).  
Table 3 about here 
Since polymyxins are currently used to treat carbapenem-resistant infections, the SR 
monotherapy would substitute for polymyxins in the treatment of CRAB, and hence the new 
therapy would reduce the selection pressure on organisms to develop polymyxin-resistance. 
Thus, the new therapy would improve the treatment success rate of infections that are often 
treated with polymyxins. The diversity savings and benefits in the context of this example relate 
to the effects of the reduction in polymyxin use and the subsequent reduction in resistance.  
The basis for calculation of this benefit is the total European ICU population. We calculate the 
number of ICU infections resistant to carbapenems (i.e., the number of ICU infections that are 
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likely to be treated with polymyxins) and multiply that population by the estimated average 
cost savings and QALYs gained from reducing the selection pressure on polymyxins. The 
equations we use are listed as (9) and (10): 
Diversity Savings (Sd) = Estimated no. ICU stays × carbapenem prescription rate ×         
carbapenem resistance rate × cost of treating resistant case × estimated reduction in 
costs of treating ICU HAIs.          (9) 
 
Diversity benefits (Vd) = Estimated no. ICU stays × carbapenem prescription rate × 
carbapenem resistance rate × life years gained × utility value of quality of life gained × 
estimated reduction in mortality of ICU HAIs                                                                      (10) 
In the absence of a polymyxin prescription rate, the carbapenem prescription and resistance 
rates are used as a proxy, as polymyxins are likely to be used to treat carbapenem-resistance 
ICU infections. To estimate the number of European ICU stays, we used figures from a 
reference concerning the number of ICU beds across a number of European countries31 and 
applied ICU occupancy rates from another source32. In the case of a real therapy we would 
recommend performing a formal expert elicitation to assess the extent of mortality and cost 
reductions resulting from reduced selection pressure, but as the technology to be evaluated in 
this case is hypothetical, we asked a clinical expert to provide us with a reasonable range of 
numbers.  Our parameter estimates are shown in Table 4. Note that they are not based on an 
assumption that the SR monotherapy will eliminate polymyxin-resistance, but that it will 
reduce the selection pressure on polymyxins such that treatment costs reduce by 5-8% and 
mortality reduces by 2.5-3.5%. 
Table 4 about here 
Author TB is employed by Hoffman-La Roche and his participation in this project is as in-kind 
contribution to the project by his employer.  Other than that, the funding source had no role in 
the study. 
Results 
We used the above reasoning to assess direct, transmission and diversity cost, savings and 
benefits. Table 5 summarises these calculated estimates for the parameter ranges given in tables 
2, 3 and 4.  High cost and low benefits/ savings estimates are pessimistic; low cost and high 
benefits/ savings estimates are optimistic.  
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Table 5. about here 
We used these numbers to calculate a cost per QALY saved for the SR monotherapy which 
reflects the multiple sources of value as per Recommendation 3.  The point estimate is €3,661 
per QALY.  Figure 1. shows ICERS calculated using only the “Direct” only components, 
“Direct + transmission” components, and “Direct + transmission + diversity” components, 
highlighting the important of considering the transmission benefits in a comprehensive 
analysis.    
Following Recommendation 2, our estimates are calculated at the population level and Figures 
2. and 3. give insight into the scale and composition of these numbers by showing the 
breakdown of the benefits and how the different sorts of savings (partially) compensate for the 
treatment costs.  (In Figure 2., the direct component of the value is represented by the grey 
area, the transmission component by the white area, and the diversity component by the black 
area of the bar.)   
Recommendation 1 is to perform sensitivity analysis to account for resistance.  As resistance 
rates are hard to predict due to fundamental scientific uncertainty, as well as uncertainty about 
background conditions in the health system, we stress that such sensitivity analysis should not 
be seen as a forecast, but rather as a “what-if” tool which can be used to sensitise decision 
makers to possible future experience with this technology.  Note that if only direct costs and 
benefits are considered, increasing resistance will reduce the population treated, but will not 
necessarily change the cost-effectiveness calculation (as population size appears in the 
numerator and denominator of the cost-effectiveness ratio and so cancels out).  However, if our 
three categories of costs and benefits are considered, as not all these are directly proportional 
to population treated, resistance may affect the cost-effectiveness ratio in ways which are hard 
to predict.  A simple way to illustrate this is to reduce each of three categories of costs and 
benefits by a fixed factor over time (reflecting the decline of the size of the population enjoying 
the benefit or incurring the cost).  To make this point clear, if we apply an annual decay of 5%, 
8% and 3% for direct, transmission and diversity benefit respectively, we get the following 
trajectory for costs and benefits over fifteen years as shown in Figure 5.  This shows that, given 
these numbers, the gap between the costs and benefits increases as the years progress (in fact 
the cost-effectiveness worsens from €3,661 to €7,067 per QALY by year 15). 
Figures 1, 2, 3, and 4 about here 
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In the context of this example, ignoring transmission and diversity effects in the analysis will 
have a substantial impact on both accept/ reject decisions and pricing decisions, and 
specifically would lead to rejecting or underpricing a welfare-improving technology.  Although 
the analysis is for a notional rather than a real technology, this observation is fully consistent 
with the qualitative policy discourse in this area which stresses how ignoring the wider effects 
of antibiotics has led to chronic underinvestment in this critically important area of technology.    
Discussion 
This paper looks for a middle course between theory-based directives from health economics 
that are challenging to implement, and pragmatic rule-based approaches to evaluating 
antibiotics that ignore the role of AMR entirely. It is important to realise that all such 
assessments of antibiotics are conditional on an assumed treatment scenario: more conservative 
use for example may increase V and Vt in the long run, but may compromise Vd.  This 
underscores that there has to be close coordination between the agency making the 
reimbursement decision and the agencies responsible for the development of treatment 
guidelines, and for monitoring compliance.    
Although the recommendations we proposed in the Framework section of the paper are not 
consistent with current HTA practice, HTA agencies will have to include such considerations 
if the full value of new antibiotic therapies are to be recognised in decision making.  Moreover, 
taking these considerations into account is logically implied by the background health 
economic theory which is supposed to guide and give normative authority to HTA.   
It is true that advocates of many other therapeutic areas often present arguments as to why these 
are also considered unique and, therefore, should be assessed differently by HTA authorities 
(e.g. orphan drugs, targeted oncology medicines and agents targeting neurodegenerative 
diseases). However, as argued in the previous literature, there are sound health economic 
grounds for considering an expanded concept of value such as the one proposed in this paper, 
and implementing these methodologies is not an insurmountable feat.  Accordingly our answer 
to the question of the title of this paper is that HTA agencies should evaluate the unique 
attributes of novel antibiotics, in a way which takes into consideration the full economic and 
societal value of these important technologies to patients, health care systems and society. 
Otherwise, the value of these essential medicines could be substantially under-recognised, 
leading to continued market failure, under-investment and inadequate innovation to address the 
problem of rising antimicrobial resistance. 
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Table 1: European CRAB incidence estimates  
 Point estimate Source 
Annual Healthcare 
associated infection 
incidence in Europe 4,000,000 
ECDC 
% of Acinetobacter 
baumannii infections 2.7% 
ECDC 
Carbapenem resistance 
rate 40% 
ECDC 
Annual incidence of 
CRAB infections in 
Europe 43,200 
Estimated  
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Table 2: Parameters used to estimate direct costs and savings  
 
Point 
estimate Low High 
Source 
Cost of treating resistant case  €14,913 €1,000 €25,685 
Adapted 
from SR 
Cost of novel therapy  €25,000 €8,900 €40,000 
Adapted 
from SR 
Reduced transmission rate  40%    Estimated 
Reduced mortality rate 10%   SR 
Cost reduction per effective 
therapy 50%   
SR 
Life years gained 8 6 10 SR 
Utility value of quality of life 
gained 0.6 0.4 0.8 
SR 
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Table 3: Parameters used to estimate transmission costs and savings  
 
  
 Point estimate Low High Source 
CRAB incidence 43,200   ECDC 
Reduced transmission rate 40%   Estimated 
Cost of treating resistant case €14,913 €1,000 €25,685 
Adapted from 
SR 
CRAB mortality rate 20%   
SR, ICU 
estimates 
Life years gained from avoided 
infection 12   
SR, ICU 
estimates 
Utility value of quality of life 
gained from avoided infection 0.8   
SR, ICU 
estimates 
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Table 4: Parameters used to estimate diversity benefits 
 
 
Point 
estimate Low High 
Source 
Estimated no. ICU stays 1,910,975   Estimated 
Carbapenem prescription 
rate 2.5% 1% 5.5% 
ECDC 
Carbapenem resistance 
rate 40%   
ECDC 
Cost of treating resistant 
case €14,913 €1,000 €25,685 
Adjusted 
from SR 
Estimated reduction in 
costs of treating ICU 
HAIs 7% 5% 8% 
Expert 
judgement 
Estimated reduction in 
mortality of ICUs HAIs 3% 2.5% 3.5% 
Expert 
judgement 
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Table 5.  Costs, Savings and Benefits 
 
 Point estimate Optimistic Pessimistic 
Direct cost (C, mEUR) 648 231 1,037 
Direct savings (S, mEUR) 193 333 13 
Direct benefits (V) 12,442 20,736 6,221 
Transmission savings (St, 
mEUR) 258 444 17 
Transmission benefits (Vt) 33,178 33,178 33,178 
Diversity Savings (Sd, mEUR) 20 86 0 
Diversity benefits (Vd) 2,752 11,772 459 
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Figure 1: ICERs from considering only the “Direct” only components, “Direct + 
transmission” components, and “Direct + transmission + diversity” components 
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Figure 2.  Breakdown of total benefit by type of value 
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Figure 3.  Display how savings from avoided illness might mitigate treatment cost 
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Figure 4.  Sensitivity analysis to show possible effects of resistance over time 
 
 
 
 
   
